Chemotherapy for Advanced Malignant Mixed Mullerian Tumours
Author Information
Author(s): Kosmas C, Vorgias G, Tsakonas G, Politis P, Daladimos T, Panagiotidi E, Papachrysanthou T, Moschovis D, Kalinoglou N, Tsavaris N, Karabelis A, Mylonakis N
Primary Institution: ‘Metaxa’ Cancer Hospital, Piraeus, Greece
Hypothesis
The study evaluates the effectiveness of the paclitaxel–ifosfamide–carboplatin combination in patients with advanced malignant mixed Mullerian tumours (MMMTs).
Conclusion
The TICb combination showed significant activity with manageable toxicity in women with advanced MMMTs.
Supporting Evidence
- 67.5% of patients responded to the treatment.
- The median overall survival was 18 months.
- Grade 3/4 neutropenia occurred in 55% of patients.
Takeaway
This study tested a new combination of chemotherapy drugs on women with a serious type of cancer, and it worked well without causing too many bad side effects.
Methodology
Patients with advanced MMMTs were treated with a combination of paclitaxel, ifosfamide, and carboplatin, and their responses were evaluated.
Potential Biases
Potential bias due to the single-institution study design.
Limitations
The study was limited to a single institution and may not be generalizable to all patients with MMMTs.
Participant Demographics
Median age was 58 years, with 90% having a WHO performance status of 0 or 1.
Statistical Information
P-Value
p<0.05
Confidence Interval
95% CI, 53–82%
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website